Affidea PET-CT expands its portfolio of excellence and innovation services in Madrid

The company has new facilities at 14 Modesto La Fuente street, where they have incorporated two radiopharmaceuticals: PSMA and Ga-68 DOTATOC.

Affidea PET-CT, Madrid has expanded its portfolio of services at its facilities at 14 Modesto La Fuente street, incorporating two radiopharmaceuticals: PSMA and Ga-68 DOTATOC.

The vast majority of PET-CT studies are performed by intravenous injection of glucose labeled with a radioactive isotope (F-18-FDG (fluorine-deoxyglucose). This compound accumulates in areas with increased metabolism.

In oncology, its main application, this compound makes it possible to study the initial extension of tumors, to evaluate the effectiveness of treatment and to identify possible tumor recurrence, in an early manner, in relation to other imaging techniques: CT, ECO, MRI.